Naringenin Sensitizes Resistant C6 Glioma Cells with a Repressive Impact on the Migrating Ability

BACKGROUND: Glioma, the most common form of a malignant brain tumour is characterised by a poor prognosis, which is attributable to its resistance against current therapeutic approaches. Temozolomide (TMZ), a DNA alkylating agent, is the first-line drug for glioma treatment. Long-term treatment usin...

Descripción completa

Detalles Bibliográficos
Autores principales: J, Jayalakshmi, Vanisree, Arambakkam Janardhanam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455008/
https://www.ncbi.nlm.nih.gov/pubmed/34556949
http://dx.doi.org/10.1177/0972753120950057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455008/
https://www.ncbi.nlm.nih.gov/pubmed/34556949
http://dx.doi.org/10.1177/0972753120950057

Ejemplares similares